Oral JAK Therapy Expands. Topical Treatment Still Needs Its Own Evidence.
Two new EU indications for oral upadacitinib raise a practical question for topical development: which patients, sites and outcomes can a local treatment address?
One oral drug, two clinical questions
On July 29, 2026, AbbVie announced European Commission approval of oral upadacitinib (Rinvoq) for two additional indications: severe alopecia areata in adults and adolescents aged 12 or older, and non-segmental vitiligo in the same age group when systemic treatment is appropriate. The European Medicines Agency’s current product information lists both indications. [1, 2, 3]
The trials asked different questions. The alopecia studies assessed scalp hair coverage at week 24. The vitiligo studies assessed body and facial repigmentation at week 48. Those endpoints cannot be placed on one scale to rank the two diseases, and neither approval is a head-to-head comparison with a topical medicine. [1, 2]
A cream has a defined place, not a universal answer
The EU-authorised ruxolitinib cream Opzelura shows how specific a topical treatment can be. For non-segmental vitiligo with facial involvement, its instructions call for twice-daily application and limit the area treated at one time to 10% of the body. Satisfactory repigmentation may take more than six months. These are conditions for that medicine, not a template for every topical product. [4]
An oral option does not make local treatment obsolete. Nor does applying a medicine to skin establish that it has lower risk or adequate exposure at its target. Patient selection, affected area, treatment burden and safety need to be judged for each product and disease.
The development question is more precise
A topical program should identify the intended tissue, the finished formulation, its use schedule and the outcome that matters to patients. For scalp disease, measuring an ingredient in a bottle cannot show exposure near the relevant follicular structures. For vitiligo, application area and a long treatment course shape both formulation and clinical evaluation. These are development questions, not claims that any particular delivery platform has solved them.